Literature DB >> 11121133

Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.

P M Lacal1, C M Failla, E Pagani, T Odorisio, C Schietroma, S Falcinelli, G Zambruno, S D'Atri.   

Abstract

The vascular endothelial growth factor is produced by a large variety of human tumors, including melanoma, in which it appears to play an important role in the process of tumor-induced angiogenesis. Little information is available on the role of placenta growth factor, a member of the vascular endothelial growth factor family of cytokines, in tumor angiogenesis, even though placenta growth factor/vascular endothelial growth factor heterodimers have been recently isolated from tumor cells. To investigate the role of placenta growth factor and vascular endothelial growth factor homodimers and heterodimers in melanoma angiogenesis and growth, 19 human melanoma cell lines derived from primary or metastatic tumors were characterized for the expression of these cytokines and their receptors. Release of placenta growth factor and vascular endothelial growth factor polypeptides into the supernatant of human melanoma cells was demonstrated. Reverse transcriptase polymerase chain reaction analysis showed the presence of mRNAs encoding at least three different vascular endothelial growth factor isoforms (VEGF(121), VEGF(165), and VEGF(189)) and transcripts for two placenta growth factor isoforms (PlGF-1 and PlGF-2) in human melanoma cells. In addition, placenta growth factor expression in human melanoma in vivo was detected by immunohistochemical staining of tumor specimens. Both primary and metastatic melanoma cells were found to express the mRNAs encoding for vascular endothelial growth factor and placenta growth factor receptors (KDR, Flt-1, neuropilin-1, and neuropilin-2), and exposure of melanoma cells to these cytokines resulted in a specific proliferative response, supporting the hypothesis of a role of these angiogenic factors in melanoma growth. J Invest Dermatol 115:1000-1007 2000

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121133     DOI: 10.1046/j.1523-1747.2000.00199.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  45 in total

1.  Functional significance of VEGFR-2 on ovarian cancer cells.

Authors:  Whitney A Spannuth; Alpa M Nick; Nicholas B Jennings; Guillermo N Armaiz-Pena; Lingegowda S Mangala; Christopher G Danes; Yvonne G Lin; William M Merritt; Premal H Thaker; Aparna A Kamat; Liz Y Han; James R Tonra; Robert L Coleman; Lee M Ellis; Anil K Sood
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

2.  Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor.

Authors:  Marcella Marcellini; Naomi De Luca; Teresa Riccioni; Alessandro Ciucci; Angela Orecchia; Pedro Miguel Lacal; Federica Ruffini; Maurizio Pesce; Francesca Cianfarani; Giovanna Zambruno; Augusto Orlandi; Cristina Maria Failla
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 3.  Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?

Authors:  Iris Helfrich; Dirk Schadendorf
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

4.  Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression.

Authors:  Dingzhi Wang; Haibin Wang; Yong Guo; Wei Ning; Sharada Katkuri; Walter Wahli; Beatrice Desvergne; Sudhansu K Dey; Raymond N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

5.  BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

Authors:  Kevin B Kim; Jeffrey A Sosman; John P Fruehauf; Gerald P Linette; Svetomir N Markovic; David F McDermott; Jeffrey S Weber; Hoa Nguyen; Peter Cheverton; Daniel Chen; Amy C Peterson; William E Carson; Steven J O'Day
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

6.  Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors.

Authors:  Zhican Qu; Sabrina Van Ginkel; Anshu M Roy; Louise Westbrook; Mubina Nasrin; Yulia Maxuitenko; Andra R Frost; Delicia Carey; Wenquan Wang; Rongbao Li; William E Grizzle; Jaideep V Thottassery; Francis G Kern
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Targeted therapy in melanoma.

Authors:  Hussein Tawbi; Neelima Nimmagadda
Journal:  Biologics       Date:  2009-12-29

8.  Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma.

Authors:  Femke Heindryckx; Koen Mertens; Nicolas Charette; Bert Vandeghinste; Christophe Casteleyn; Christophe Van Steenkiste; Dominique Slaets; Louis Libbrecht; Steven Staelens; Peter Starkel; Anja Geerts; Isabelle Colle; Hans Van Vlierberghe
Journal:  Mol Cancer       Date:  2010-08-20       Impact factor: 27.401

9.  Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Authors:  Domingo G Perez; Vera J Suman; Tom R Fitch; Thomas Amatruda; Roscoe F Morton; Shamim Z Jilani; Costas L Constantinou; James R Egner; Lisa A Kottschade; Svetomir N Markovic
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

10.  Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo.

Authors:  Debora Faraone; Maria Simona Aguzzi; Gabriele Toietta; Angelo M Facchiano; Francesco Facchiano; Alessandra Magenta; Fabio Martelli; Silvia Truffa; Eleonora Cesareo; Domenico Ribatti; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.